{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:34:26Z","timestamp":1761057266108},"reference-count":19,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2002,5,7]],"date-time":"2002-05-07T00:00:00Z","timestamp":1020729600000},"content-version":"vor","delay-in-days":36,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Transplantation"],"published-print":{"date-parts":[[2002,4]]},"abstract":"<jats:p><jats:bold>Abstract:<\/jats:bold>  Everolimus (Certican; RAD), a novel macrolide with potent immunosuppressive and anti\u2010proliferative activities, prevents acute rejection in adult recipients of renal transplantation. This phase I trial conducted in stable pediatric renal transplant patients examined the single\u2010dose pharmacokinetics, safety, and tolerability of everolimus in combination with cyclosporin A (CsA; Neoral<jats:sup>\u00ae<\/jats:sup>) and corticosteroids, with or without azathioprine. Nineteen pediatric patients were enrolled and received a single 1.2\u2003mg\/m<jats:sup>2<\/jats:sup> dose of everolimus. Everolimus was safe and well tolerated, with a low incidence of adverse events reported and none judged to be related to the study medication. Everolimus administration did not increase infection rates or produce clinically significant changes in vital signs or changes in electrocardiograms. Apparent clearance and volume of distribution of everolimus increased with age, weight, and body surface area in a generally linear manner across the pediatric demographic ranges. Compared with adults from a previous study, apparent clearance (L\/h) and distribution volume (L) were lower in pediatric patients, whereas the elimination half\u2010life was similar. Single\u2010dose everolimus co\u2010administration did not affect the steady\u2010state pharmacokinetics of CsA. Based on this information, pediatric patients will need a dose scaled down for body size, but can probably maintain the same twice\u2010daily dosing schedule used in adults.<\/jats:p>","DOI":"10.1034\/j.1399-3046.2002.01070.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T18:58:38Z","timestamp":1047495518000},"page":"147-152","source":"Crossref","is-referenced-by-count":27,"title":["Single\u2010dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients"],"prefix":"10.1034","volume":"6","author":[{"given":"R.","family":"VanDamme\u2010Lombaerts","sequence":"first","affiliation":[]},{"given":"N.","family":"Webb","sequence":"additional","affiliation":[]},{"given":"P. F.","family":"Hoyer","sequence":"additional","affiliation":[]},{"given":"J.","family":"Mahan","sequence":"additional","affiliation":[]},{"given":"J.","family":"Lemire","sequence":"additional","affiliation":[]},{"given":"R.","family":"Ettenger","sequence":"additional","affiliation":[]},{"given":"L.","family":"McMahon","sequence":"additional","affiliation":[]},{"given":"N.","family":"Cambon","sequence":"additional","affiliation":[]},{"given":"R.","family":"Boger","sequence":"additional","affiliation":[]},{"given":"J. M.","family":"Kovarik","sequence":"additional","affiliation":[]},{"name":"for the Everolimus Study Group","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2002,5,7]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199707150-00008"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(98)00587-9"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199512000-00019"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(98)00589-2"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(98)00590-9"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199707150-00007"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200105270-00008"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00852872"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199803150-00003"},{"key":"e_1_2_7_11_2","first-page":"8","article-title":"15 years of pediatric heart transplantation at the University of Pittsburgh: lessons learned and future prospects","volume":"1","author":"Webber SA","year":"1997","journal-title":"Pediatr Transpl"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1995.326"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00085.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199910270-00007"},{"volume-title":"Rapamune (Sirolimus) Oral Solution Prescribing Information.","year":"1999","author":"Grimm E","key":"e_1_2_7_15_2"},{"key":"e_1_2_7_16_2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/ajhp\/57.5.437","article-title":"Sirolimus: a new agent for prevention of renal allograft rejection","volume":"57","author":"Vasquez EM","year":"2000","journal-title":"Am J Health Syst Pharm"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3046.1999.00036.x"},{"issue":"2","key":"e_1_2_7_18_2","first-page":"86","article-title":"Sirolimus pharmacokinetics in pediatric renal transplants [Abstract 0121]","volume":"4","author":"Grimm EM","year":"2000","journal-title":"Pediatr Transplantation"},{"key":"e_1_2_7_19_2","first-page":"35","article-title":"Cyclosporin A (Neoral\u00ae) in pediatric organ transplantation","volume":"2","author":"Hoyer PF","year":"1998","journal-title":"Pediatr Transplantation"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.1996.tb00991.x"}],"container-title":["Pediatric Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1399-3046.2002.01070.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1399-3046.2002.01070.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T19:21:06Z","timestamp":1697570466000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1399-3046.2002.01070.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["10.1034\/j.1399-3046.2002.01070.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1399-3046.2002.01070.x","archive":["Portico"],"relation":{},"ISSN":["1397-3142","1399-3046"],"issn-type":[{"type":"print","value":"1397-3142"},{"type":"electronic","value":"1399-3046"}],"subject":[],"published":{"date-parts":[[2002,4]]}}}